Skip to content

Study for evaluating the safety of excessive intake of food containing plant-derived constituent

Study for evaluating the safety of excessive intake of food containing plant-derived constituent - Study for evaluating the safety of excessive intake of food

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000033873
Enrollment
40
Registered
2018-09-01
Start date
2018-09-06
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None (Healthy adults)

Interventions

Food containing plant-derived constituent, 12 portion of food per day for 4 weeks. Placebo food, 12 portion of food per day for 4 weeks.

Sponsors

KSO Co., Ltd
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: (1)Healthy males and females aged from 20 to less than 65 years old when giving the informed consent. (2)Subjects with BMI from 18.5 to less than 30 kg/m2 at the screening. (3)Subjects giving the informed consents in writing after receiving explanation of the purpose and details of the study, understanding the study and deciding to attend the study with their own will.

Exclusion criteria

Exclusion criteria: (1)Subjects on a diet. (2)Subjects using medication affecting lipid metabolism. (3)Subjects constantly using supplements or functional foods affecting lipid metabolism (including foods for specified health uses and foods with function claims). (4)Subjects using foods containing ingredients of test food constantly. (5)Subjects with excessive alcohol-drinking behaviors (maximum daily quantity: approximately 20 g of pure alcohol per day). (6)Subjects who cannot stop drinking for two days until the screening and each checkup. (7)Subjects with food allergy. (8)Subjects with serious diseases (e.g., diabetes, kidney disease, liver disease, and/or heart disease), thyroid gland disease, adrenal gland disease, and/or metabolic disorders. (9)Subjects with chronic diseases and using medicines continuously. (10)Subjects having a medical history of diseases affecting digestion and absorption. (11)Subjects with implantable medical devices (e.g., cardiac pace maker and implantable defibrillator) (12)Subjects judged unsuitable for the study based on the results of blood test. (13)Subjects with anemia. (14)Subjects having donated over 200 mL of blood or blood component within the last one month prior to the current study or over 400 mL of blood or blood component within the last three months prior to the current study. (15)Subjects diagnosed with familial hyperlipidemia. (16)Subjects under treatment or a history of drug addiction and/or alcoholism. (17)Subjects participating or willing to participate in other clinical studies with the intake of food or pharmaceutical products, or with the swab of cosmetic or pharmaceutical products. (18)Subjects who are pregnant, breastfeeding, or planning to be pregnant in the near future. (19)Subjects working for a company developing or manufacturing functional foods. (20)Subjects judged unsuitable for this study by the investigator for other reasons.

Design outcomes

Primary

MeasureTime frame
1. Interview by physician 2. Height and body weight 3. Blood pressure and pulse 4. Hematological test 5. Biochemical test 6. Urine analysis 7. Subjective symptom and objective response 8. Adverse events

Countries

Japan

Contacts

Public ContactEiji Yoshikawa

KSO Corporation Sales Department

yoshikawa@kso.co.jp03-3452-7733

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026